Second- and third-line therapy in gastric cancer/new options for therapy

被引：0
|
作者：
Schmalenberg, H. [1 ]
机构：
[1] Krankenhaus Dresden Friedrichstadt, Med Klin 4, Dresden, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V435
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [21] Third-line therapy for metastatic colorectal cancer
    Gundgaard, M. G.
    Soerensen, J. B.
    Ehrnrooth, E.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (01) : 1 - 13
  • [22] Therapy of malignant melanoma. First-, second- and pathogenesis-oriented third-line therapies
    Rass, K.
    Tadler, D.
    Tilgen, W.
    [J]. HAUTARZT, 2006, 57 (09): : 773 - +
  • [23] Second- or Third-Line Therapy of non-operable, locally advanced or metastatic Renal Cell Carcinoma
    Rexer, Heidrun
    Retz, Margitta
    Steiner, Thomas
    [J]. AKTUELLE UROLOGIE, 2021, 52 (05) : 425 - 426
  • [24] Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings
    Giantonio, Bruce J.
    [J]. SEMINARS IN ONCOLOGY, 2006, 33 (05) : S15 - S18
  • [25] Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer
    Oh, Yun
    Herbst, Roy S.
    Burris, Howard
    Cleverly, Ann
    Musib, Luna
    Lahn, Michael
    Bepler, Gerold
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) : 1135 - 1141
  • [26] A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
    Kang, Yoon-Koo
    Muro, Kei
    Ryu, Min-Hee
    Yasui, Hirofumi
    Nishina, Tomohiro
    Ryoo, Baek-Yeol
    Kamiya, Yukimasa
    Akinaga, Shiro
    Boku, Narikazu
    [J]. INVESTIGATIONAL NEW DRUGS, 2014, 32 (02) : 355 - 361
  • [27] Second- and third-line treatments in non-small cell lung cancer
    Kumar A.
    Wakelee H.
    [J]. Current Treatment Options in Oncology, 2006, 7 (1) : 37 - 49
  • [28] A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer
    Yoon-Koo Kang
    Kei Muro
    Min-Hee Ryu
    Hirofumi Yasui
    Tomohiro Nishina
    Baek-Yeol Ryoo
    Yukimasa Kamiya
    Shiro Akinaga
    Narikazu Boku
    [J]. Investigational New Drugs, 2014, 32 : 355 - 361
  • [29] Rituximab for the second- and third-line therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy
    Busch, Martin
    Ruester, Christiane
    Schinkoethe, Claudia
    Gerth, Jens
    Wolf, Gunter
    [J]. CLINICAL NEPHROLOGY, 2013, 80 (02) : 105 - 113
  • [30] Chemothery (pacitaxol or irinotecan), plus apatinib and sintilimab as second-/third-line treatment for advanced gastric cancer.
    Deng, Ting
    Zhang, Le
    Duan, Jingjing
    Li, Hongli
    Ge, Shaohua
    Bai, Ming
    Ning, Tao
    Yang, Yuchong
    Ji, Zhi
    Liu, Rui
    Wang, Xia
    Zhang, Haiyang
    Ba, Yi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345